 Victoria Pelak
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vision Disorders | 13 | 2023 | 137 | 2.920 |
Why?
| | Alzheimer Disease | 8 | 2023 | 509 | 2.460 |
Why?
| | Neurodegenerative Diseases | 4 | 2022 | 89 | 2.180 |
Why?
| | Eye Movements | 3 | 2021 | 58 | 1.400 |
Why?
| | Cerebral Cortex | 6 | 2022 | 497 | 1.230 |
Why?
| | Atrophy | 4 | 2022 | 158 | 1.100 |
Why?
| | Eye Diseases | 2 | 2020 | 82 | 0.960 |
Why?
| | Lewy Body Disease | 2 | 2020 | 15 | 0.920 |
Why?
| | Cognitive Dysfunction | 3 | 2023 | 316 | 0.880 |
Why?
| | Tremor | 2 | 2021 | 48 | 0.850 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 9 | 0.830 |
Why?
| | Ocular Motility Disorders | 4 | 2018 | 26 | 0.830 |
Why?
| | Nervous System Diseases | 2 | 2020 | 265 | 0.830 |
Why?
| | Fragile X Syndrome | 1 | 2021 | 73 | 0.810 |
Why?
| | Visual Perception | 2 | 2022 | 162 | 0.790 |
Why?
| | Macular Degeneration | 1 | 2022 | 153 | 0.760 |
Why?
| | Reading | 1 | 2021 | 170 | 0.740 |
Why?
| | Mucolipidoses | 1 | 2019 | 7 | 0.740 |
Why?
| | Tomography, Optical Coherence | 4 | 2022 | 133 | 0.720 |
Why?
| | Visual Pathways | 3 | 2018 | 44 | 0.700 |
Why?
| | Dementia | 2 | 2011 | 222 | 0.650 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 366 | 0.650 |
Why?
| | Coronavirus Infections | 2 | 2020 | 356 | 0.650 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.640 |
Why?
| | Migraine Disorders | 1 | 2018 | 83 | 0.630 |
Why?
| | Ophthalmology | 1 | 2018 | 77 | 0.620 |
Why?
| | Visual Fields | 5 | 2022 | 80 | 0.620 |
Why?
| | Neurology | 1 | 2018 | 91 | 0.620 |
Why?
| | Androgens | 1 | 2016 | 175 | 0.530 |
Why?
| | Aging | 3 | 2023 | 1692 | 0.500 |
Why?
| | Optic Neuropathy, Ischemic | 3 | 2012 | 28 | 0.490 |
Why?
| | Pandemics | 2 | 2020 | 1316 | 0.460 |
Why?
| | Testosterone | 1 | 2016 | 371 | 0.450 |
Why?
| | Humans | 45 | 2023 | 121869 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 9 | 2019 | 3240 | 0.380 |
Why?
| | Optic Nerve Diseases | 2 | 2009 | 32 | 0.370 |
Why?
| | Cognition | 2 | 2023 | 1083 | 0.370 |
Why?
| | Optic Neuritis | 3 | 2020 | 35 | 0.370 |
Why?
| | Inflammation | 1 | 2020 | 2522 | 0.360 |
Why?
| | Vision, Low | 1 | 2009 | 13 | 0.360 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2020 | 39 | 0.360 |
Why?
| | Optic Nerve | 1 | 2009 | 66 | 0.350 |
Why?
| | Giant Cell Arteritis | 3 | 2020 | 46 | 0.310 |
Why?
| | Brain Diseases | 2 | 2017 | 149 | 0.310 |
Why?
| | Congresses as Topic | 2 | 2019 | 218 | 0.300 |
Why?
| | Visual Acuity | 6 | 2022 | 277 | 0.290 |
Why?
| | Cataract Extraction | 1 | 2006 | 79 | 0.270 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 21 | 0.250 |
Why?
| | Nerve Net | 2 | 2022 | 264 | 0.250 |
Why?
| | Male | 22 | 2022 | 60475 | 0.240 |
Why?
| | Aged | 11 | 2023 | 20705 | 0.240 |
Why?
| | Cognition Disorders | 2 | 2023 | 592 | 0.230 |
Why?
| | Cognitive Aging | 1 | 2023 | 14 | 0.230 |
Why?
| | Immunosuppressive Agents | 4 | 2020 | 681 | 0.220 |
Why?
| | Lewy Bodies | 1 | 2022 | 4 | 0.220 |
Why?
| | Unconsciousness | 1 | 2022 | 26 | 0.220 |
Why?
| | Amnesia | 2 | 2012 | 45 | 0.210 |
Why?
| | Ataxia | 1 | 2021 | 42 | 0.210 |
Why?
| | Middle Aged | 16 | 2022 | 28961 | 0.210 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 91 | 0.210 |
Why?
| | Trochlear Nerve Diseases | 1 | 2001 | 5 | 0.210 |
Why?
| | Diffusion Tensor Imaging | 2 | 2023 | 87 | 0.210 |
Why?
| | Abducens Nerve Diseases | 1 | 2001 | 9 | 0.200 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2021 | 64 | 0.200 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2001 | 9 | 0.200 |
Why?
| | Neuropsychological Tests | 3 | 2022 | 1140 | 0.200 |
Why?
| | White Matter | 1 | 2023 | 128 | 0.200 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 18 | 0.190 |
Why?
| | Stents | 2 | 2016 | 476 | 0.190 |
Why?
| | Female | 21 | 2023 | 63903 | 0.190 |
Why?
| | Autonomic Fibers, Preganglionic | 1 | 1999 | 4 | 0.190 |
Why?
| | Siderosis | 1 | 1999 | 3 | 0.190 |
Why?
| | Pupil | 1 | 1999 | 15 | 0.190 |
Why?
| | Eye Movement Measurements | 1 | 2019 | 12 | 0.180 |
Why?
| | Immunomodulation | 1 | 2020 | 85 | 0.180 |
Why?
| | Brain Stem | 1 | 2000 | 105 | 0.180 |
Why?
| | West Nile Fever | 1 | 2020 | 52 | 0.180 |
Why?
| | Brain | 6 | 2023 | 2693 | 0.180 |
Why?
| | Hearing Loss | 1 | 2023 | 180 | 0.180 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2019 | 36 | 0.180 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 157 | 0.180 |
Why?
| | Steroids | 1 | 2020 | 158 | 0.180 |
Why?
| | San Francisco | 1 | 2018 | 57 | 0.170 |
Why?
| | Immune System | 1 | 2020 | 182 | 0.170 |
Why?
| | Facial Recognition | 1 | 2019 | 34 | 0.170 |
Why?
| | Frontotemporal Dementia | 1 | 2019 | 35 | 0.170 |
Why?
| | Facial Expression | 1 | 2019 | 76 | 0.160 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2018 | 43 | 0.160 |
Why?
| | Vestibule, Labyrinth | 1 | 2018 | 52 | 0.160 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 24 | 0.150 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.150 |
Why?
| | Critical Care | 1 | 2021 | 528 | 0.150 |
Why?
| | Papilledema | 2 | 2018 | 36 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 493 | 0.140 |
Why?
| | Universities | 1 | 2018 | 363 | 0.140 |
Why?
| | Adult | 13 | 2022 | 32683 | 0.140 |
Why?
| | Laser Therapy | 1 | 2017 | 105 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2021 | 3314 | 0.140 |
Why?
| | Amygdala | 1 | 2017 | 184 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2006 | 2322 | 0.140 |
Why?
| | Brain Mapping | 3 | 2022 | 594 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2018 | 329 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1012 | 0.120 |
Why?
| | Multiple Sclerosis | 3 | 2020 | 375 | 0.120 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2023 | 91 | 0.110 |
Why?
| | Biomedical Research | 1 | 2019 | 632 | 0.110 |
Why?
| | Optic Disk Drusen | 1 | 2012 | 5 | 0.110 |
Why?
| | Autoantibodies | 2 | 2018 | 1333 | 0.110 |
Why?
| | Visual Field Tests | 1 | 2011 | 14 | 0.110 |
Why?
| | Cranial Sinuses | 1 | 2011 | 12 | 0.110 |
Why?
| | Optic Disk | 2 | 2009 | 35 | 0.110 |
Why?
| | Hemianopsia | 1 | 2011 | 10 | 0.110 |
Why?
| | Hippocampus | 1 | 2017 | 797 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2020 | 13063 | 0.110 |
Why?
| | Hemodynamics | 1 | 2016 | 1047 | 0.110 |
Why?
| | Memory, Episodic | 1 | 2012 | 45 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2453 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1425 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 165 | 0.090 |
Why?
| | Biomarkers | 1 | 2020 | 3652 | 0.090 |
Why?
| | Stiff-Person Syndrome | 1 | 2008 | 6 | 0.090 |
Why?
| | Nervous System Malformations | 1 | 2009 | 33 | 0.090 |
Why?
| | Hypokinesia | 1 | 2008 | 8 | 0.090 |
Why?
| | Age of Onset | 2 | 2020 | 479 | 0.080 |
Why?
| | Rest | 2 | 2022 | 134 | 0.070 |
Why?
| | Arteritis | 1 | 2006 | 28 | 0.070 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 30 | 0.070 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 45 | 0.070 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 121 | 0.060 |
Why?
| | Animals | 4 | 2023 | 34134 | 0.060 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1965 | 0.060 |
Why?
| | Gliosis | 1 | 2023 | 37 | 0.060 |
Why?
| | Neurites | 1 | 2023 | 43 | 0.060 |
Why?
| | Adolescent | 6 | 2020 | 19126 | 0.060 |
Why?
| | Pulvinar | 1 | 2022 | 5 | 0.050 |
Why?
| | Young Adult | 4 | 2022 | 11223 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4883 | 0.050 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 176 | 0.050 |
Why?
| | Diplopia | 1 | 2001 | 16 | 0.050 |
Why?
| | Strabismus | 1 | 2001 | 26 | 0.050 |
Why?
| | Neuroimaging | 1 | 2023 | 255 | 0.050 |
Why?
| | Treatment Failure | 2 | 2016 | 343 | 0.050 |
Why?
| | Functional Laterality | 1 | 2022 | 223 | 0.050 |
Why?
| | Connectome | 1 | 2022 | 70 | 0.050 |
Why?
| | Vision Tests | 1 | 2000 | 13 | 0.050 |
Why?
| | Vision, Ocular | 1 | 2000 | 33 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 84 | 0.050 |
Why?
| | Temporal Lobe | 2 | 2012 | 100 | 0.050 |
Why?
| | Demyelinating Diseases | 1 | 2020 | 77 | 0.050 |
Why?
| | New Orleans | 1 | 2019 | 13 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 55 | 0.040 |
Why?
| | Encephalitis | 1 | 2020 | 125 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 247 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 1002 | 0.040 |
Why?
| | Focus Groups | 1 | 2018 | 382 | 0.040 |
Why?
| | Transfection | 1 | 2018 | 919 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2018 | 655 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 9776 | 0.030 |
Why?
| | Patient Participation | 1 | 2018 | 371 | 0.030 |
Why?
| | Hospital Mortality | 1 | 1999 | 878 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1108 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 792 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 891 | 0.030 |
Why?
| | Child | 3 | 2020 | 19282 | 0.030 |
Why?
| | Emotions | 1 | 2019 | 530 | 0.030 |
Why?
| | Color Vision Defects | 1 | 2012 | 6 | 0.030 |
Why?
| | Spinal Puncture | 1 | 2012 | 16 | 0.030 |
Why?
| | Colorado | 1 | 2022 | 4344 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 608 | 0.030 |
Why?
| | Phlebography | 1 | 2011 | 36 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 2011 | 116 | 0.030 |
Why?
| | Lymphokines | 1 | 1991 | 124 | 0.020 |
Why?
| | Stroke | 1 | 1999 | 1067 | 0.020 |
Why?
| | Hospitalization | 1 | 1999 | 1873 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4922 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3078 | 0.020 |
Why?
| | Autoradiography | 1 | 1989 | 79 | 0.020 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2008 | 6 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1991 | 376 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1383 | 0.020 |
Why?
| | Blindness | 1 | 2008 | 35 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1989 | 153 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1989 | 139 | 0.020 |
Why?
| | Saccades | 1 | 2008 | 52 | 0.020 |
Why?
| | Oculomotor Muscles | 1 | 2008 | 41 | 0.020 |
Why?
| | Withholding Treatment | 1 | 2008 | 68 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 1991 | 380 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2008 | 164 | 0.020 |
Why?
| | Frontal Lobe | 1 | 1989 | 164 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2008 | 128 | 0.020 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 160 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2008 | 168 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1472 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1991 | 620 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 1991 | 1069 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1871 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 345 | 0.020 |
Why?
| | Cohort Studies | 1 | 2016 | 5300 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2011 | 9654 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 11 | 0.020 |
Why?
| | Sural Nerve | 1 | 2005 | 20 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 48 | 0.020 |
Why?
| | Graves Disease | 1 | 2005 | 32 | 0.020 |
Why?
| | Hypertrophy | 1 | 2005 | 125 | 0.020 |
Why?
| | Amino Acids | 1 | 1989 | 458 | 0.020 |
Why?
| | Myelin Sheath | 1 | 2005 | 146 | 0.020 |
Why?
| | Axons | 1 | 2005 | 185 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2999 | 0.010 |
Why?
| | Mice | 1 | 2020 | 15621 | 0.010 |
Why?
| | Disease Progression | 1 | 2008 | 2582 | 0.010 |
Why?
| | Contrast Sensitivity | 1 | 2000 | 13 | 0.010 |
Why?
| | Observer Variation | 1 | 2000 | 316 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2008 | 1553 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 804 | 0.010 |
Why?
| | Walking | 1 | 2000 | 434 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2519 | 0.010 |
Why?
| | Age Factors | 1 | 1999 | 3173 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 5663 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 87 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 201 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1991 | 81 | 0.010 |
Why?
| | Receptors, IgG | 1 | 1991 | 67 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1991 | 77 | 0.010 |
Why?
| | CD3 Complex | 1 | 1991 | 92 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1991 | 45 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 303 | 0.010 |
Why?
| | Base Sequence | 1 | 1991 | 2217 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1991 | 2948 | 0.000 |
Why?
| | Gene Expression | 1 | 1991 | 1530 | 0.000 |
Why?
| | RNA | 1 | 1991 | 860 | 0.000 |
Why?
|
|
Pelak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|